HAMI-3379
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530954

CAS#: 712313-33-2

Description: HAMI-3379, also known as BayCysLT2; C633; CAY10633, is a CysLT2R antagonist. HAMI-3379 dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. HAMI 3379 attenuates ischemia-like neuronal injury by inhibiting microglial activation. HAMI 3379 protects against acute brain injury after focal cerebral ischemia in rats.


Price and Availability

Size
Price

5mg
USD 365
Size
Price

10mg
USD 585
Size
Price

HAMI-3379, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530954
Name: HAMI-3379
CAS#: 712313-33-2
Chemical Formula: C34H39NO8
Exact Mass: 589.2676
Molecular Weight: 589.685
Elemental Analysis: C, 69.25; H, 6.67; N, 2.38; O, 21.71


Synonym: CAY10633; CAY-10633; CAY 10633; BayCysLT2; C633; C-633; C 633; HAMI-3379; HAMI 3379; HAMI3379.

IUPAC/Chemical Name: 3-[[(3-Carboxycyclohexyl)amino]carbonyl]-4-[3-[4-(4-phenoxybutoxy)phenyl]propoxy]-benzoic acid

InChi Key: GKPAULTWHHPIHX-UHFFFAOYSA-N

InChi Code: InChI=1S/C34H39NO8/c36-32(35-27-10-6-9-25(22-27)33(37)38)30-23-26(34(39)40)15-18-31(30)43-21-7-8-24-13-16-29(17-14-24)42-20-5-4-19-41-28-11-2-1-3-12-28/h1-3,11-18,23,25,27H,4-10,19-22H2,(H,35,36)(H,37,38)(H,39,40)

SMILES Code: O=C(O)C1=CC=C(OCCCC2=CC=C(OCCCCOC3=CC=CC=C3)C=C2)C(C(NC4CC(C(O)=O)CCC4)=O)=C1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Chen L, Yang Y, Li CT, Zhang SR, Zheng W, Wei EQ, Zhang LH. CysLT2 receptor mediates lipopolysaccharide-induced microglial inflammation and consequent neurotoxicity in vitro. Brain Res. 2015 Oct 22;1624:433-45. doi: 10.1016/j.brainres.2015.08.007. Epub 2015 Aug 15. PubMed PMID: 26282348.

2: Shi QJ, Wang H, Liu ZX, Fang SH, Song XM, Lu YB, Zhang WP, Sa XY, Ying HZ, Wei EQ. HAMI 3379, a CysLT2R antagonist, dose- and time-dependently attenuates brain injury and inhibits microglial inflammation after focal cerebral ischemia in rats. Neuroscience. 2015 Apr 16;291:53-69. doi: 10.1016/j.neuroscience.2015.02.002. Epub 2015 Feb 11. PubMed PMID: 25681271.

3: Xu DM, Zhang XY, Wang XR, Chen L, Zhang LH, Shi QJ, Fang SH, Lu YB, Zhang WP, Wei EQ. [Antioxidative effects of cysteinyl leukotriene receptor antagonists montelukast and HAMI 3379 on ischemic injury in rat cortical neurons in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2014 May;43(3):257-64. Chinese. PubMed PMID: 24998647.

4: Lin K, Fang S, Cai B, Huang X, Zhang X, Lu Y, Zhang W, Wei E. ERK/Egr-1 signaling pathway is involved in CysLT2 receptor-mediated IL-8 production in HEK293 cells. Eur J Cell Biol. 2014 Jul;93(7):278-88. doi: 10.1016/j.ejcb.2014.05.001. Epub 2014 May 20. PubMed PMID: 24925646.

5: Yu SY, Zhang XY, Wang XR, Xu DM, Chen L, Zhang LH, Fang SH, Lu YB, Zhang WP, Wei EQ. Cysteinyl leukotriene receptor 1 mediates LTD4-induced activation of mouse microglial cells in vitro. Acta Pharmacol Sin. 2014 Jan;35(1):33-40. doi: 10.1038/aps.2013.130. Epub 2013 Oct 21. PubMed PMID: 24141567; PubMed Central PMCID: PMC4075749.

6: Zhang Z, Luo J, Huang J, Liu Z, Fang S, Zhang WP, Wei E, Lu Y. [Leukotriene D4 activates BV2 microglia in vitro]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2013 May;42(3):253-60. Chinese. PubMed PMID: 23801612.

7: Zhang XY, Wang XR, Xu DM, Yu SY, Shi QJ, Zhang LH, Chen L, Fang SH, Lu YB, Zhang WP, Wei EQ. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation. J Pharmacol Exp Ther. 2013 Aug;346(2):328-41. doi: 10.1124/jpet.113.203604. Epub 2013 Jun 7. PubMed PMID: 23750020.

8: Shi QJ, Xiao L, Zhao B, Zhang XY, Wang XR, Xu DM, Yu SY, Fang SH, Lu YB, Zhang WP, Sa XY, Wei EQ. Intracerebroventricular injection of HAMI 3379, a selective cysteinyl leukotriene receptor 2 antagonist, protects against acute brain injury after focal cerebral ischemia in rats. Brain Res. 2012 Nov 12;1484:57-67. doi: 10.1016/j.brainres.2012.09.020. Epub 2012 Sep 18. PubMed PMID: 23000196.

9: Wunder F, Tinel H, Kast R, Geerts A, Becker EM, Kolkhof P, Hütter J, Ergüden J, Härter M. Pharmacological characterization of the first potent and selective antagonist at the cysteinyl leukotriene 2 (CysLT(2)) receptor. Br J Pharmacol. 2010 May;160(2):399-409. doi: 10.1111/j.1476-5381.2010.00730.x. PubMed PMID: 20423349; PubMed Central PMCID: PMC2874861.